OpenURL Connection Search

Select item for more details and to access through your institution.

PP2A: the Achilles heal in MDS with 5q deletion.
Published in:
Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00264
By:
- Sallman, David A.;
- ShengWei;
- Alan List
Publication type:
Article
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Published in:
International Journal of Molecular Sciences, 2021, v. 22, n. 18, p. 10105, doi. 10.3390/ijms221810105
By:
- Cluzeau, Thomas;
- Loschi, Michael;
- Fenaux, Pierre;
- Komrokji, Rami;
- Sallman, David A.
Publication type:
Article
TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q).
Published in:
British Journal of Haematology, 2024, v. 204, n. 4, p. 1243, doi. 10.1111/bjh.19247
By:
- Tefferi, Ayalew;
- Fleti, Farah;
- Chan, Onyee;
- Al Ali, Najla H.;
- Al‐Kali, Aref;
- Begna, Kebede H.;
- Foran, James M.;
- Badar, Talha;
- Khera, Nandita;
- Shah, Mithun;
- Hiwase, Devendra;
- Padron, Eric;
- Sallman, David A.;
- Pardanani, Animesh;
- Arber, Daniel A.;
- Orazi, Attilio;
- Reichard, Kaaren K.;
- He, Rong;
- Ketterling, Rhett P.;
- Gangat, Naseema
Publication type:
Article
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy‐related myelodysplastic syndromes.
Published in:
British Journal of Haematology, 2022, v. 198, n. 4, p. 713, doi. 10.1111/bjh.18319
By:
- Volpe, Virginia O.;
- Al Ali, Najla;
- Chan, Onyee;
- Padron, Eric;
- Sallman, David A.;
- Kuykendall, Andrew;
- Sweet, Kendra;
- Lancet, Jeffrey E.;
- Komrokji, Rami S.
Publication type:
Article
Expanding the immune armoury against myelodysplastic syndrome.
Published in:
British Journal of Haematology, 2021, v. 195, n. 3, p. 301, doi. 10.1111/bjh.17711
By:
- Sallman, David A.;
- Ball, Somedeb
Publication type:
Article
Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.
Published in:
British Journal of Haematology, 2019, v. 184, n. 3, p. 450, doi. 10.1111/bjh.15099
By:
- McGraw, Kathy L.;
- Nguyen, Johnny;
- Al Ali, Najla H.;
- Komrokji, Rami S.;
- Sallman, David;
- Zhang, Xiaohui;
- Song, Jinming;
- Padron, Eric;
- Lancet, Jeffrey E.;
- Moscinski, Lynn C.;
- List, Alan F.;
- Zhang, Ling
Publication type:
Article
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Published in:
American Journal of Hematology, 2024, v. 99, n. 10, p. 1870, doi. 10.1002/ajh.27417
By:
- Garciaz, Sylvain;
- Dumas, Pierre‐Yves;
- Bertoli, Sarah;
- Sallman, David A.;
- Decroocq, Justine;
- Belhabri, Amine;
- Orvain, Corentin;
- Aspas Requena, Gaspar;
- Simand, Celestine;
- Laribi, Kamel;
- Carré, Martin;
- Santagostino, Alberto;
- Himberlin, Chantal;
- Peterlin, Pierre;
- Bonnet, Sarah;
- Chan, Onyee;
- Lancet, Jeffrey;
- Komrokji, Rami;
- Vergez, François;
- Chapuis, Nicolas
Publication type:
Article
Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia.
Published in:
American Journal of Hematology, 2023, v. 98, n. 12, p. E360, doi. 10.1002/ajh.27092
By:
- Patel, Parth C.;
- Ball, Somedeb;
- Jain, Akriti G.;
- Wang, Chen;
- Hussaini, Mohammad O.;
- Aguirre, Luis E.;
- Chan, Onyee;
- Yun, Seongseok;
- Kuykendall, Andrew;
- Padron, Eric;
- Sweet, Kendra;
- Lancet, Jeffrey E.;
- Komrokji, Rami S.;
- Sallman, David A.
Publication type:
Article
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative cases.
Published in:
American Journal of Hematology, 2023, v. 98, n. 4, p. E76, doi. 10.1002/ajh.26845
By:
- Fleti, Farah;
- Chan, Onyee;
- Singh, Amritpal;
- Abdelmagid, Maymona G.;
- Al‐Kali, Aref;
- Elliott, Michelle A.;
- Begna, Kebede H.;
- Foran, James M.;
- Badar, Talha;
- Khera, Nandita;
- Al Ali, Najla H.;
- Padron, Eric;
- Sallman, David A.;
- Shah, Mithun;
- Hiwase, Devendra;
- Pardanani, Animesh;
- Arber, Daniel A.;
- Orazi, Attilio;
- Reichard, Kaaren K.;
- He, Rong
Publication type:
Article
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Published in:
American Journal of Hematology, 2022, v. 97, n. 5, p. E185, doi. 10.1002/ajh.26504
By:
- Ball, Somedeb;
- Jain, Akriti G.;
- Aguirre, Luis E.;
- Al Ali, Najla;
- Zhang, Yumeng;
- Chan, Onyee;
- Kuykendall, Andrew T.;
- Sweet, Kendra L.;
- Lancet, Jeffrey E.;
- Swoboda, David M.;
- Padron, Eric;
- Komrokji, Rami S.;
- Sallman, David A.
Publication type:
Article
Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia.
Published in:
American Journal of Hematology, 2021, v. 96, n. 4, p. 462, doi. 10.1002/ajh.26110
By:
- Richardson, Daniel R.;
- Swoboda, David M.;
- Moore, Dominic T.;
- Johnson, Steven M.;
- Chan, Onyee;
- Galeotti, Jonathan;
- Esparza, Sonia;
- Hussaini, Mohammad O.;
- Van Deventer, Hendrick;
- Foster, Matthew C.;
- Coombs, Catherine C.;
- Montgomery, Nathan D.;
- Sallman, David A.;
- Zeidner, Joshua F.
Publication type:
Article
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Published in:
Annals of Hematology, 2024, v. 103, n. 6, p. 1941, doi. 10.1007/s00277-024-05760-6
By:
- Jain, Akriti G;
- Gesiotto, Quinto;
- Ball, Somedeb;
- Nodzon, Lisa;
- Rodriguez, Amanda;
- Chan, Onyee;
- Padron, Eric;
- Kuykendall, Andrew;
- Komrokji, Rami;
- Sallman, David A.;
- Lancet, Jeffrey E;
- Pinilla-Ibarz, Javier;
- Sweet, Kendra
Publication type:
Article
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Published in:
Annals of Hematology, 2024, v. 103, n. 1, p. 117, doi. 10.1007/s00277-023-05564-0
By:
- Horvat, Nathan P.;
- Abdallah, Enas F.;
- Xie, Zhuoer;
- Al Ali, Najla;
- Yun, Seongseok;
- Walker, Alison;
- Padron, Eric;
- Sallman, David;
- Chan, Onyee;
- Lancet, Jeffrey;
- Komrokji, Rami;
- Kuykendall, Andrew T.
Publication type:
Article
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.
Published in:
2018
By:
- Kuykendall, Andrew T.;
- Shah, Savan;
- Talati, Chetasi;
- Al Ali, Najla;
- Sweet, Kendra;
- Padron, Eric;
- Sallman, David A.;
- Lancet, Jeffrey E.;
- List, Alan F.;
- Zuckerman, Kenneth S.;
- Komrokji, Rami S.
Publication type:
journal article
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
Published in:
European Journal of Haematology, 2021, v. 107, n. 6, p. 609, doi. 10.1111/ejh.13698
By:
- Song, Amy;
- Altabbakh, Omar;
- Sallman, David A.;
- Padron, Eric;
- Talati, Chetasi;
- Hussaini, Mohammad O.
Publication type:
Article
Clonal selection in therapy‐related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Published in:
European Journal of Haematology, 2020, v. 104, n. 5, p. 488, doi. 10.1111/ejh.13390
By:
- Calleja, Anne;
- Yun, Seongseok;
- Moreilhon, Chimène;
- Karsenti, Jean Michel;
- Gastaud, Lauris;
- Mannone, Lionel;
- Komrokji, Rami;
- Ali, Najla;
- Dadone‐montaudie, Bérangère;
- Robert, Guillaume;
- Auberger, Patrick;
- Raynaud, Sophie;
- Sallman, David A.;
- Cluzeau, Thomas
Publication type:
Article
Examining disparities in large‐scale patient‐reported data capture using digital tools among cancer patients at clinical intake.
Published in:
Cancer Medicine, 2023, v. 12, n. 18, p. 19033, doi. 10.1002/cam4.6459
By:
- Rollison, Dana E.;
- Gonzalez, Brian D.;
- Turner, Kea;
- Jim, Heather S. L.;
- Zhao, Yayi;
- Amorrortu, Rossybelle P.;
- Howard, Rachel;
- Ghia, Kavita M.;
- Ngo, Bryan;
- Reisman, Phillip;
- Moore, Colin;
- Perkins, Randa;
- Keenan, Robert J.;
- Sallman, David A.;
- Naso, Cristina M.;
- Robinson, Edmondo J.;
- Vadaparampil, Susan T.;
- Simmons, Vani N.;
- Schabath, Matthew B.;
- Gilbert, Scott M.
Publication type:
Article
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
Published in:
Cancer Medicine, 2021, v. 10, n. 2, p. 447, doi. 10.1002/cam4.3608
By:
- Komrokji, Rami S.;
- Al Ali, Najla H;
- Sallman, David;
- Padron, Eric;
- DeZern, Amy E.;
- Barnard, John;
- Roboz, Gail J.;
- Garcia‐Manero, Guillermo;
- List, Alan;
- Steensma, David P.;
- Sekeres, Mikkael A.
Publication type:
Article
Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Published in:
European Journal of Haematology, 2019, v. 102, n. 3, p. 203, doi. 10.1111/ejh.13207
By:
- Lee, Jung‐hoon;
- List, Alan;
- Sallman, David A.
Publication type:
Article
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Published in:
Current Treatment Options in Oncology, 2023, v. 24, n. 5, p. 387, doi. 10.1007/s11864-023-01062-7
By:
- Wang, Chen;
- Sallman, David A.
Publication type:
Article
Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Published in:
Cancer Biology & Medicine, 2016, v. 13, p. 360, doi. 10.20892/j.issn.2095-3941.2016.0043
By:
- Clara, Joseph A.;
- Sallman, David A.;
- Padron, Eric
Publication type:
Article
Unraveling the Pathogenesis of MDS: The NLRP3 inflammasome and Pyroptosis Drive the MDS Phenotype.
Published in:
Frontiers in Oncology, 2016, p. 1, doi. 10.3389/fonc.2016.00151
By:
- Sallman, David A.;
- List, Alan;
- Cluzeau, Thomas;
- Basiorka, Ashley A.
Publication type:
Article
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 7, p. 459, doi. 10.1016/j.clml.2024.03.001
By:
- Aguirre, Luis E.;
- Jain, Akriti;
- Ball, Somedeb;
- Ali, Najla Al;
- Volpe, Virginia O.;
- Tinsley-Vance, Sara;
- Sallman, David;
- Sweet, Kendra;
- Lancet, Jeffrey;
- Padron, Eric;
- Yun, Seongseok;
- Kuykendall, Andrew;
- Komrokji, Rami
Publication type:
Article
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 400, doi. 10.1016/j.clml.2024.02.005
By:
- Ionescu, Filip;
- David, Jerel C.;
- Ravichandran, Apoorva;
- Sallman, David A.;
- Sweet, Kendra;
- Komrokji, Rami S.;
- Chan, Onyee;
- Kuykendall, Andrew;
- Padron, Eric;
- Faramand, Rawan;
- Bejanyan, Nelli;
- Khimani, Farhad;
- Elmariah, Hany;
- Pidala, Joseph;
- Mishra, Asmita;
- Perez, Lia;
- Nishihori, Taiga;
- Lancet, Jeffrey E.
Publication type:
Article
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 4, p. 260, doi. 10.1016/j.clml.2023.12.008
By:
- Rajakumaraswamy, Nishanthan;
- Gandhi, Mitul;
- Wei, Andrew H.;
- Sallman, David A.;
- Daver, Naval G.;
- Mo, Shuyuan;
- Iqbal, Shahed;
- Karalliyadda, Roshan;
- Chen, Manli;
- Wang, Yunfei;
- Vyas, Paresh
Publication type:
Article
Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 10, p. e315, doi. 10.1016/j.clml.2023.07.002
By:
- Jain, Akriti G.;
- Ball, Somedeb;
- Aguirre, Luis E.;
- Tobon, Katherine A.;
- Chan, Onyee;
- Padron, Eric;
- Kuykendall, Andrew;
- Komrokji, Rami;
- Sallman, David;
- Lancet, Jeffrey E.;
- Sweet, Kendra
Publication type:
Article
Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 355, doi. 10.1016/j.clml.2023.01.007
By:
- Tinsley-Vance, Sara M;
- Ali, Najla Al;
- Ball, Somedeb;
- Aguirre, Luis E;
- Jain, Akriti G;
- Hussaini, Mohammad Omar;
- Chan, Onyee;
- Kuykendall, Andrew;
- Sweet, Kendra;
- Lancet, Jeffrey;
- Padron, Eric;
- Sallman, David A;
- Komrokji, Rami S
Publication type:
Article
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. e150, doi. 10.1016/j.clml.2022.12.008
By:
- Zhang, Yumeng;
- Nguyen, Lynn;
- Lu, Chuanyi M.;
- Wang, Endi;
- Lauw, Marietya I.S.;
- Ball, Somedeb;
- Dong, Ning;
- Moscinski, Lynn;
- Chan, Onyee;
- Yun, Seongseok;
- Sallman, David;
- Sokol, Lubomir;
- Shah, Bijal;
- Knepper, Todd;
- Lancet, Jeffery;
- Komrokji, Rami;
- Padron, Eric;
- Kuykendall, Andrew;
- Zhang, Ling
Publication type:
Article
Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis.
Published in:
2023
By:
- Hasegawa, Ken;
- Wei, Andrew H;
- Garcia-Manero, Guillermo;
- Daver, Naval G;
- Rajakumaraswamy, Nishanthan;
- Iqbal, Shahed;
- Chan, Rebecca J;
- Hu, Hao;
- Tse, Preston;
- Yan, Jiajun;
- Zoratti, Michael J;
- Xie, Feng;
- Sallman, David A
Publication type:
journal article
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 10, p. 774, doi. 10.1016/j.clml.2022.06.001
By:
- Lee, Dasom;
- Jain, Akriti G;
- Deutsch, Yehuda;
- Eatrides, Jennifer;
- Chan, Onyee;
- Padron, Eric;
- Kuykendall, Andrew;
- Komrokji, Rami;
- Lancet, Jeffrey;
- Sallman, David;
- Talati, Chetasi;
- Sweet, Kendra
Publication type:
Article
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e521, doi. 10.1016/j.clml.2022.01.015
By:
- Tokumori, Franco Castillo;
- Ali, Najla Al;
- Chan, Onyee;
- Sallman, David;
- Yun, Seongseok;
- Sweet, Kendra;
- Padron, Eric;
- Lancet, Jeffrey;
- Komrokji, Rami;
- Kuykendall, Andrew T.
Publication type:
Article
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e467, doi. 10.1016/j.clml.2022.01.002
By:
- Chan, Onyee;
- Ali, Najla Al;
- Sallman, David;
- Padron, Eric;
- Lancet, Jeffrey;
- Komrokji, Rami
Publication type:
Article
MPN-236: Different Treatment Approaches to Blast-Phase Myeloproliferative Neoplasms.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S358, doi. 10.1016/S2152-2650(21)01825-5
By:
- Tokumori, Franco Castillo;
- Talati, Chetasi;
- Ali, Najla Al;
- Sallman, David;
- Yun, Seongseok;
- Sweet, Kendra;
- Padron, Eric;
- Lancet, Jeffrey;
- Komrokji, Rami;
- Kuykendall, Andrew
Publication type:
Article
MPN-244: Comorbid Conditions Occur Frequently and Correlate with Early Disease Progression and Poor Outcomes in Young Patients with Myelofibrosis.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S358, doi. 10.1016/S2152-2650(21)01826-7
By:
- Horvat, Nathan P.;
- Komrokji, Rami;
- Ali, Najla Al;
- Talati, Chetasi;
- Padron, Eric;
- Sallman, David;
- Sweet, Kendra;
- Chan, Onyee;
- Lancet, Jeffrey;
- Kuykendall, Andrew T.
Publication type:
Article
MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S344, doi. 10.1016/S2152-2650(21)01801-2
By:
- Aguirre, Luis E.;
- Ball, Somedeb;
- Ali, Najla Al;
- Sallman, David A.;
- Kuykendall, Andrew T.;
- Sweet, Kendra;
- Lancet, Jeffrey E.;
- Padron, Eric;
- Komrokji, Rami
Publication type:
Article
MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S343, doi. 10.1016/S2152-2650(21)01799-7
By:
- Garcia-Manero, Guillermo;
- Daver, Naval;
- Xu, Jin;
- Chao, Mark;
- Chung, Trisha;
- Tan, Anderson;
- Wang, Yan;
- Wei, Andrew;
- Vyas, Paresh;
- Sallman, David
Publication type:
Article
MDS-128: Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S341, doi. 10.1016/S2152-2650(21)01794-8
By:
- Ali, Najla Al;
- Sallman, David;
- Onyee Chan;
- Padron, Eric;
- Sweet, Kendra;
- Kuykendall, Andrew;
- Lancet, Jeffrey;
- Komrokji, Rami
Publication type:
Article
AML-407: Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S309, doi. 10.1016/S2152-2650(21)01733-X
By:
- Chan, Onyee;
- Ali, Najla Al;
- Yun, Seongseok;
- Talati, Chetasi;
- Kuykendall, Andrew;
- Padron, Eric;
- Sallman, David;
- Sweet, Kendra;
- Komrokji, Rami;
- Lancet, Jeffrey
Publication type:
Article
AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S293, doi. 10.1016/S2152-2650(21)01700-6
By:
- Ball, Somedeb;
- Jain, Akriti G.;
- Al Ali, Najla;
- Hayden, Alexander;
- Swoboda, David M;
- Aguirre, Luis E;
- Sallman, David A;
- Padron, Eric;
- Sweet, Kendra;
- Lancet, Jeffrey E;
- Watts, Justin;
- Pollyea, Daniel A;
- Komrokji, Rami S
Publication type:
Article
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S290, doi. 10.1016/S2152-2650(21)01694-3
By:
- Sallman, David;
- Asch, Adam;
- Kambhampati, Suman;
- Al Malki, Monzr;
- Zeidner, Joshua;
- Donnellan, William;
- Lee, Daniel;
- Vyas, Paresh;
- Jeyakumar, Deepa;
- Mannis, Gabriel;
- Tanaka, Tiffany;
- Wanxing Chai-Ho;
- Larson, Richard;
- Whiteley, Andrew;
- Marcucci, Guido;
- Komrokji, Rami;
- Garcia-Manero, Guillermo;
- Van Elk, Joanna;
- Ming Lin;
- Maute, Roy
Publication type:
Article
AML-170: High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S286, doi. 10.1016/S2152-2650(21)01686-4
By:
- Volpe, Virginia;
- Vincelette, Nicole;
- Logothetis, Constantine;
- Onyee Chan;
- Talati, Chetasi;
- Sweet, Kendra;
- Calon, Gregoire;
- Horvat, Nathan;
- Kuykendall, Andrew;
- Sallman, David;
- Padron, Eric;
- Komrokji, Rami;
- Ling Zhang;
- Lancet, Jeffrey;
- Seongseok Yun
Publication type:
Article
Poster: MPN-244: Comorbid Conditions Occur Frequently and Correlate with Early Disease Progression and Poor Outcomes in Young Patients with Myelofibrosis.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01460-9
By:
- Horvat, Nathan P.;
- Komrokji, Rami;
- Ali, Najla Al;
- Talati, Chetasi;
- Padron, Eric;
- Sallman, David;
- Sweet, Kendra;
- Onyee Chan;
- Lancet, Jeffrey;
- Kuykendall, Andrew T.
Publication type:
Article
Poster: MPN-236: Different Treatment Approaches to Blast-Phase Myeloproliferative Neoplasms.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01459-2
By:
- Tokumori, Franco Castillo;
- Talati, Chetasi;
- Ali, Najla Al;
- Sallman, David;
- Seongseok Yun;
- Sweet, Kendra;
- Padron, Eric;
- Lancet, Jeffrey;
- Komrokji, Rami;
- Kuykendall, Andrew
Publication type:
Article
Poster: MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01449-X
By:
- Garcia-Manero, Guillermo;
- Daver, Naval;
- Jin Xu;
- Chao, Mark;
- Chung, Trisha;
- Tan, Anderson;
- Yan Wang;
- Wei, Andrew;
- Vyas, Paresh;
- Sallman, David
Publication type:
Article
Poster: MDS-128: Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S226, doi. 10.1016/S2152-2650(21)01428-2
By:
- Al Ali, Najla;
- Sallman, David;
- Onyee Chan;
- Padron, Eric;
- Sweet, Kendra;
- Kuykendall, Andrew;
- Lancet, Jeffrey;
- Komrokji, Rami
Publication type:
Article
Poster: MDS-229: Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S227, doi. 10.1016/S2152-2650(21)01433-6
By:
- Aguirre, Luis E.;
- Ball, Somedeb;
- Al Ali, Najla;
- Sallman, David A.;
- Kuykendall, Andrew T.;
- Sweet, Kendra;
- Lancet, Jeffrey E.;
- Padron, Eric;
- Komrokji, Rami
Publication type:
Article
Poster: AML-407: Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S214, doi. 10.1016/S2152-2650(21)01345-8
By:
- Chan, Onyee;
- Ali, Najla Al;
- Yun, Seongseok;
- Talati, Chetasi;
- Kuykendall, Andrew;
- Padron, Eric;
- Sallman, David;
- Sweet, Kendra;
- Komrokji, Rami;
- Lancet, Jeffrey
Publication type:
Article
Poster: AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S213, doi. 10.1016/S2152-2650(21)01337-9
By:
- Sallman, David;
- Asch, Adam;
- Kambhampati, Suman;
- Malki, Monzr Al;
- Zeidner, Joshua;
- Donnellan, William;
- Lee, Daniel;
- Vyas, Paresh;
- Jeyakumar, Deepa;
- Mannis, Gabriel;
- Tanaka, Tiffany;
- Chai-Ho, Wanxing;
- Larson, Richard;
- Whiteley, Andrew;
- Marcucci, Guido;
- Komrokji, Rami;
- Garcia-Manero, Guillermo;
- Van Elk, Joanna;
- Lin, Ming;
- Maute, Roy
Publication type:
Article
Poster: AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S213, doi. 10.1016/S2152-2650(21)01340-9
By:
- Ball, Somedeb;
- Jain, Akriti G.;
- Ali, Najla Al;
- Hayden, Alexander;
- Swoboda, David M;
- Aguirre, Luis E.;
- Sallman, David A;
- Padron, Eric;
- Sweet, Kendra;
- Lancet, Jeffrey E;
- Watts, Justin;
- Pollyea, Daniel A;
- Komrokji, Rami S
Publication type:
Article
Poster: AML-170: High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S212, doi. 10.1016/S2152-2650(21)01331-8
By:
- Volpe, Virginia;
- Vincelette, Nicole;
- Logothetis, Constantine;
- Chan, Onyee;
- Talati, Chetasi;
- Sweet, Kendra;
- Calon, Gregoire;
- Horvat, Nathan;
- Kuykendall, Andrew;
- Sallman, David;
- Padron, Eric;
- Komrokji, Rami;
- Zhang, Ling;
- Lancet, Jeffrey;
- Yun, Seongseok
Publication type:
Article

Found: 105